{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T13:39:05Z","timestamp":1791639545261,"version":"4.3.4"},"reference-count":122,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2022,6,5]],"date-time":"2022-06-05T00:00:00Z","timestamp":1654387200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>Mosquito-borne flavivirus infections affect approximately 400 million people worldwide each year and are global threats to public health. The common diseases caused by such flaviviruses include West Nile, yellow fever, dengue, Zika infection and Japanese encephalitis, which may result in severe symptoms and disorders of multiple organs or even fatal outcomes. Till now, no specific antiviral agents are commercially available for the treatment of the diseases. Numerous strategies have been adopted to develop novel and promising inhibitors against mosquito-borne flaviviruses, including drugs targeting the critical viral components or essential host factors during infection. Research advances in antiflaviviral therapy might optimize and widen the treatment options for flavivirus infection. This review summarizes the current developmental progresses and involved molecular mechanisms of antiviral agents against mosquito-borne flaviviruses.<\/jats:p>","DOI":"10.3390\/v14061226","type":"journal-article","created":{"date-parts":[[2022,6,5]],"date-time":"2022-06-05T10:47:11Z","timestamp":1654426031000},"page":"1226","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":49,"title":["Mosquito-Borne Flaviviruses and Current Therapeutic Advances"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9654-1260","authenticated-orcid":false,"given":"Xijing","family":"Qian","sequence":"first","affiliation":[{"name":"Department of Microbiology, Faculty of Naval Medicine, Naval Medical University, Shanghai 200433, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongtian","family":"Qi","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Faculty of Naval Medicine, Naval Medical University, Shanghai 200433, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,6,5]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"131","DOI":"10.2174\/1874357901812010131","article-title":"Impact of Emerging, Re-Emerging and Zoonotic Viral Infectious Diseases, in a Virologist\u2019s Perspective","volume":"12","author":"Kobayashi","year":"2018","journal-title":"Open Virol. J."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1038\/s41564-020-0714-0","article-title":"The continued threat of emerging flaviviruses","volume":"5","author":"Pierson","year":"2020","journal-title":"Nat. Microbiol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1038\/nrmicro.2017.170","article-title":"Rewiring cellular networks by members of the Flaviviridae family","volume":"16","author":"Neufeldt","year":"2018","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Carro, S.D., and Cherry, S. (2020). Beyond the Surface: Endocytosis of Mosquito-Borne Flaviviruses. Viruses, 13.","DOI":"10.3390\/v13010013"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0065-3527(03)59002-9","article-title":"Molecular biology of flaviviruses","volume":"59","author":"Lindenbach","year":"2003","journal-title":"Adv. Virus Res."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Morita, E., and Suzuki, Y. (2021). Membrane-Associated Flavivirus Replication Complex-Its Organization and Regulation. Viruses, 13.","DOI":"10.3390\/v13061060"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.micinf.2010.09.005","article-title":"Molecular mechanisms involved in the early steps of flavivirus cell entry","volume":"13","author":"Kaufmann","year":"2011","journal-title":"Microbes Infect."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1146\/annurev.mi.44.100190.003245","article-title":"Flavivirus genome organization, expression, and replication","volume":"44","author":"Chambers","year":"1990","journal-title":"Annu. Rev. Microbiol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"3963","DOI":"10.1016\/j.bmc.2019.07.038","article-title":"Peptide derivatives as inhibitors of NS2B-NS3 protease from Dengue, West Nile, and Zika flaviviruses","volume":"27","year":"2019","journal-title":"Bioorg. Med. Chem."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.antiviral.2015.03.014","article-title":"The flavivirus NS2B-NS3 protease-helicase as a target for antiviral drug development","volume":"118","author":"Luo","year":"2015","journal-title":"Antivir. Res."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"8389","DOI":"10.1021\/jm400828u","article-title":"Thiazolidinone-peptide hybrids as dengue virus protease inhibitors with antiviral activity in cell culture","volume":"56","author":"Nitsche","year":"2013","journal-title":"J. Med. Chem."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1002\/cmdc.201200497","article-title":"Development and characterization of new peptidomimetic inhibitors of the West Nile virus NS2B-NS3 protease","volume":"8","author":"Hammamy","year":"2013","journal-title":"ChemMedChem"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.antiviral.2012.02.008","article-title":"Retro peptide-hybrids as selective inhibitors of the Dengue virus NS2B-NS3 protease","volume":"94","author":"Nitsche","year":"2012","journal-title":"Antivir. Res."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"3130","DOI":"10.1016\/j.ejmech.2011.04.055","article-title":"Novel agmatine and agmatine-like peptidomimetic inhibitors of the West Nile virus NS2B\/NS3 serine protease","volume":"46","author":"Lim","year":"2011","journal-title":"Eur. J. Med. Chem."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/j.ejmech.2016.09.063","article-title":"Identification of fused bicyclic derivatives of pyrrolidine and imidazolidinone as dengue virus-2 NS2B-NS3 protease inhibitors","volume":"125","author":"Weng","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/j.bbrc.2013.03.139","article-title":"Design and evaluation of substrate-based octapeptide and non substrate-based tetrapeptide inhibitors of dengue virus NS2B-NS3 proteases","volume":"434","author":"Prusis","year":"2013","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"3586","DOI":"10.1016\/j.bmcl.2017.05.027","article-title":"Discovery of novel cyclic peptide inhibitors of dengue virus NS2B-NS3 protease with antiviral activity","volume":"27","author":"Takagi","year":"2017","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1021\/acsmedchemlett.8b00535","article-title":"De Novo Discovery of Nonstandard Macrocyclic Peptides as Noncompetitive Inhibitors of the Zika Virus NS2B-NS3 Protease","volume":"10","author":"Nitsche","year":"2019","journal-title":"ACS Med. Chem. Lett."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"12357","DOI":"10.1039\/C8CC07448H","article-title":"Broad-spectrum catalytic metallopeptide inactivators of Zika and West Nile virus NS2B\/NS3 proteases","volume":"54","author":"Pinkham","year":"2018","journal-title":"Chem. Commun."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"9354","DOI":"10.1021\/acs.jmedchem.5b01441","article-title":"Discovery of Nanomolar Dengue and West Nile Virus Protease Inhibitors Containing a 4-Benzyloxyphenylglycine Residue","volume":"58","author":"Behnam","year":"2015","journal-title":"J. Med. Chem."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1021\/acs.jmedchem.6b01021","article-title":"Peptide-Boronic Acid Inhibitors of Flaviviral Proteases: Medicinal Chemistry and Structural Biology","volume":"60","author":"Nitsche","year":"2017","journal-title":"J. Med. Chem."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"7719","DOI":"10.1021\/acs.jmedchem.5b00612","article-title":"Phenylalanine and Phenylglycine Analogues as Arginine Mimetics in Dengue Protease Inhibitors","volume":"58","author":"Weigel","year":"2015","journal-title":"J. Med. Chem."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"5714","DOI":"10.1021\/jm800503y","article-title":"Potent cationic inhibitors of West Nile virus NS2B\/NS3 protease with serum stability, cell permeability and antiviral activity","volume":"51","author":"Stoermer","year":"2008","journal-title":"J. Med. Chem."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"6585","DOI":"10.1021\/jm0607606","article-title":"Peptide inhibitors of West Nile NS3 protease: SAR study of tetrapeptide aldehyde inhibitors","volume":"49","author":"Knox","year":"2006","journal-title":"J. Med. Chem."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.antiviral.2011.07.002","article-title":"Tripeptide inhibitors of dengue and West Nile virus NS2B-NS3 protease","volume":"92","author":"Schuller","year":"2011","journal-title":"Antivir. Res."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1016\/j.str.2017.06.006","article-title":"Structural Dynamics of Zika Virus NS2B-NS3 Protease Binding to Dipeptide Inhibitors","volume":"25","author":"Li","year":"2017","journal-title":"Structure"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"6832","DOI":"10.1021\/jacs.9b02505","article-title":"X-ray Crystallography and Antiviral Activity of Allosteric Inhibitors of Flavivirus NS2B-NS3 Protease","volume":"141","author":"Yao","year":"2019","journal-title":"J. Am. Chem. Soc."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.antiviral.2011.12.003","article-title":"Use of parallel validation high-throughput screens to reduce false positives and identify novel dengue NS2B-NS3 protease inhibitors","volume":"93","author":"Tomlinson","year":"2012","journal-title":"Antivir. Res."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1038\/cr.2016.116","article-title":"Mechanisms of activation and inhibition of Zika virus NS2B-NS3 protease","volume":"26","author":"Chen","year":"2016","journal-title":"Cell Res."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"45762","DOI":"10.1074\/jbc.M107360200","article-title":"Activity of recombinant dengue 2 virus NS3 protease in the presence of a truncated NS2B co-factor, small peptide substrates, and inhibitors","volume":"276","author":"Leung","year":"2001","journal-title":"J. Biol. Chem."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/nsb0697-463","article-title":"Structure of the hepatitis C virus RNA helicase domain","volume":"4","author":"Yao","year":"1997","journal-title":"Nat. Struct. Biol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.bbrc.2014.09.113","article-title":"Suramin inhibits helicase activity of NS3 protein of dengue virus in a fluorescence-based high throughput assay format","volume":"453","author":"Basavannacharya","year":"2014","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1021\/id5000458","article-title":"Benzothiazole and Pyrrolone Flavivirus Inhibitors Targeting the Viral Helicase","volume":"1","author":"Sweeney","year":"2015","journal-title":"ACS Infect. Dis."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1081\/NCN-120023027","article-title":"5\u2032-O-fluorosulfonylbenzoyl esters of purine nucleosides as potential inhibitors of NTPase\/helicase and polymerase of Flaviviridae viruses","volume":"22","author":"Bretner","year":"2003","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1177\/095632020501600504","article-title":"Synthesis and biological activity of 1H-benzotriazole and 1H-benzimidazole analogues--inhibitors of the NTpase\/helicase of HCV and of some related Flaviviridae","volume":"16","author":"Bretner","year":"2005","journal-title":"Antivir. Chem. Chemother."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1177\/095632020401500104","article-title":"Synthesis and evaluation of ATP-binding site directed potential inhibitors of nucleoside triphosphatases\/helicases and polymerases of hepatitis C and other selected Flaviviridae viruses","volume":"15","author":"Bretner","year":"2004","journal-title":"Antivir. Chem. Chemother."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.coviro.2014.09.020","article-title":"Coupling of replication and assembly in flaviviruses","volume":"9","author":"Sirohi","year":"2014","journal-title":"Curr. Opin. Virol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"11183","DOI":"10.1128\/JVI.05468-11","article-title":"Inhibition of dengue virus by targeting viral NS4B protein","volume":"85","author":"Xie","year":"2011","journal-title":"J. Virol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"4103","DOI":"10.1128\/AAC.00074-09","article-title":"Identification of inhibitors of yellow fever virus replication using a replicon-based high-throughput assay","volume":"53","author":"Patkar","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.antiviral.2013.09.013","article-title":"Ten years of dengue drug discovery: Progress and prospects","volume":"100","author":"Lim","year":"2013","journal-title":"Antivir. Res."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.virol.2008.11.003","article-title":"A single-amino acid substitution in West Nile virus 2K peptide between NS4A and NS4B confers resistance to lycorine, a flavivirus inhibitor","volume":"384","author":"Zou","year":"2009","journal-title":"Virology"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"12943","DOI":"10.3390\/ijms160612943","article-title":"A Structural Overview of RNA-Dependent RNA Polymerases from the Flaviviridae Family","volume":"16","author":"Wu","year":"2015","journal-title":"Int. J. Mol. Sci."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1038\/nrd.2017.33","article-title":"Broad-spectrum agents for flaviviral infections: Dengue, Zika and beyond","volume":"16","author":"Boldescu","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.coviro.2014.08.004","article-title":"Inhibition of viral RNA polymerases by nucleoside and nucleotide analogs: Therapeutic applications against positive-strand RNA viruses beyond hepatitis C virus","volume":"9","author":"Deval","year":"2014","journal-title":"Curr. Opin. Virol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/978-3-540-79086-0_3","article-title":"Antiviral agents acting as DNA or RNA chain terminators","volume":"189","author":"Neyts","year":"2009","journal-title":"Handb. Exp. Pharmacol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.antiviral.2014.05.015","article-title":"Update on hepatitis C virus resistance to direct-acting antiviral agents","volume":"108","author":"Poveda","year":"2014","journal-title":"Antivir. Res."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"e02093-18","DOI":"10.1128\/AAC.02093-18","article-title":"Viral RNA-Dependent RNA Polymerase Inhibitor 7-Deaza-2\u2032-C-Methyladenosine Prevents Death in a Mouse Model of West Nile Virus Infection","volume":"63","author":"Eyer","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1016\/j.bmcl.2012.02.105","article-title":"Synthesis and antiviral activity of a series of 1\u2032-substituted 4-aza-7,9-dideazaadenosine C-nucleosides","volume":"22","author":"Cho","year":"2012","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.antiviral.2015.01.002","article-title":"Characterization of the activity of 2\u2032-C-methylcytidine against dengue virus replication","volume":"116","author":"Lee","year":"2015","journal-title":"Antivir. Res."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"2040206618761299","DOI":"10.1177\/2040206618761299","article-title":"Nucleoside analogs as a rich source of antiviral agents active against arthropod-borne flaviviruses","volume":"26","author":"Eyer","year":"2018","journal-title":"Antivir. Chem. Chemother."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1128\/AAC.04779-14","article-title":"Synergistic suppression of dengue virus replication using a combination of nucleoside analogs and nucleoside synthesis inhibitors","volume":"59","author":"Yeo","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1002\/open.201500216","article-title":"Anti-flavivirus Activity of Different Tritylated Pyrimidine and Purine Nucleoside Analogues","volume":"5","author":"McGuigan","year":"2016","journal-title":"ChemistryOpen"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.antiviral.2017.07.010","article-title":"Replication of the Zika virus in different iPSC-derived neuronal cells and implications to assess efficacy of antivirals","volume":"145","author":"Lanko","year":"2017","journal-title":"Antivir. Res."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.antiviral.2015.07.010","article-title":"The search for nucleoside\/nucleotide analog inhibitors of dengue virus","volume":"122","author":"Chen","year":"2015","journal-title":"Antivir. Res."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"2932","DOI":"10.1128\/AAC.00140-10","article-title":"Inhibition of dengue virus RNA synthesis by an adenosine nucleoside","volume":"54","author":"Chen","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"20435","DOI":"10.1073\/pnas.0907010106","article-title":"An adenosine nucleoside inhibitor of dengue virus","volume":"106","author":"Yin","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"ofw175","DOI":"10.1093\/ofid\/ofw175","article-title":"Adenosine Analog NITD008 Is a Potent Inhibitor of Zika Virus","volume":"3","author":"Deng","year":"2016","journal-title":"Open Forum Infect. Dis."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/nature13027","article-title":"Protection against filovirus diseases by a novel broad-spectrum nucleoside analogue BCX4430","volume":"508","author":"Warren","year":"2014","journal-title":"Nature"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.antiviral.2017.03.012","article-title":"Antiviral activity of the adenosine analogue BCX4430 against West Nile virus and tick-borne flaviviruses","volume":"142","author":"Eyer","year":"2017","journal-title":"Antivir. Res."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.antiviral.2016.11.003","article-title":"Efficacy of the broad-spectrum antiviral compound BCX4430 against Zika virus in cell culture and in a mouse model","volume":"137","author":"Julander","year":"2017","journal-title":"Antivir. Res."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"6607","DOI":"10.1128\/AAC.03368-14","article-title":"BCX4430, a novel nucleoside analog, effectively treats yellow fever in a Hamster model","volume":"58","author":"Julander","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1128\/AAC.01074-08","article-title":"Activity of T-705 in a hamster model of yellow fever virus infection in comparison with that of a chemically related compound, T-1106","volume":"53","author":"Julander","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.antiviral.2009.02.198","article-title":"T-705 (favipiravir) and related compounds: Novel broad-spectrum inhibitors of RNA viral infections","volume":"82","author":"Furuta","year":"2009","journal-title":"Antivir. Res."},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Matz, K., Emanuel, J., Callison, J., Gardner, D., Rosenke, R., Mercado-Hernandez, R., Williamson, B.N., Feldmann, H., and Marzi, A. (2021). Favipiravir (T-705) Protects IFNAR(-\/-) Mice against Lethal Zika Virus Infection in a Sex-Dependent Manner. Microorganisms, 9.","DOI":"10.3390\/microorganisms9061178"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s40265-014-0179-7","article-title":"Sofosbuvir: First global approval","volume":"74","author":"Keating","year":"2014","journal-title":"Drugs"},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"de Freitas, C.S., Higa, L.M., Sacramento, C.Q., Ferreira, A.C., Reis, P.A., Delvecchio, R., Monteiro, F.L., Barbosa-Lima, G., James Westgarth, H., and Vieira, Y.R. (2019). Yellow fever virus is susceptible to sofosbuvir both in vitro and in vivo. PLoS Negl. Trop. Dis., 13.","DOI":"10.1371\/journal.pntd.0007072"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"6345","DOI":"10.1038\/s41598-017-06612-2","article-title":"Evaluation of Sofosbuvir (beta-D-2\u2032-deoxy-2\u2032-alpha-fluoro-2\u2032-beta-C-methyluridine) as an inhibitor of Dengue virus replication","volume":"7","author":"Xu","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.antiviral.2016.11.023","article-title":"The FDA-approved drug sofosbuvir inhibits Zika virus infection","volume":"137","author":"Govero","year":"2017","journal-title":"Antivir. Res."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"9409","DOI":"10.1038\/s41598-017-09797-8","article-title":"Sofosbuvir protects Zika virus-infected mice from mortality, preventing short- and long-term sequelae","volume":"7","author":"Ferreira","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1093\/infdis\/jis470","article-title":"A randomized, double-blind placebo controlled trial of balapiravir, a polymerase inhibitor, in adult dengue patients","volume":"207","author":"Nguyen","year":"2013","journal-title":"J. Infect. Dis."},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Obi, J.O., Gutierrez-Barbosa, H., Chua, J.V., and Deredge, D.J. (2021). Current Trends and Limitations in Dengue Antiviral Research. Trop. Med. Infect. Dis., 6.","DOI":"10.20944\/preprints202108.0364.v1"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.antiviral.2016.09.007","article-title":"Targeting flavivirus RNA dependent RNA polymerase through a pyridobenzothiazole inhibitor","volume":"134","author":"Tarantino","year":"2016","journal-title":"Antivir. Res."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"5291","DOI":"10.1128\/JVI.00045-13","article-title":"Conformational flexibility of the Dengue virus RNA-dependent RNA polymerase revealed by a complex with an inhibitor","volume":"87","author":"Noble","year":"2013","journal-title":"J. Virol."},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Lim, S.P., Noble, C.G., Seh, C.C., Soh, T.S., El Sahili, A., Chan, G.K., Lescar, J., Arora, R., Benson, T., and Nilar, S. (2016). Potent Allosteric Dengue Virus NS5 Polymerase Inhibitors: Mechanism of Action and Resistance Profiling. PLoS Pathog., 12.","DOI":"10.1371\/journal.ppat.1005737"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"8541","DOI":"10.1074\/jbc.M115.710731","article-title":"A Conserved Pocket in the Dengue Virus Polymerase Identified through Fragment-based Screening","volume":"291","author":"Noble","year":"2016","journal-title":"J. Biol. Chem."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/978-981-10-8727-1_14","article-title":"Discovery of Potent Non-nucleoside Inhibitors of Dengue Viral RNA-Dependent RNA Polymerase from Fragment Screening and Structure-Guided Design","volume":"1062","author":"Lim","year":"2018","journal-title":"Dengue Zika Control. Antivir. Treat. Strateg."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1080\/22221751.2022.2049983","article-title":"Rifapentine is an entry and replication inhibitor against yellow fever virus both in vitro and in vivo","volume":"11","author":"Qian","year":"2022","journal-title":"Emerg. Microbes Infect."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.antiviral.2015.04.010","article-title":"The dengue virus NS5 protein as a target for drug discovery","volume":"119","author":"Lim","year":"2015","journal-title":"Antivir. Res."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.antiviral.2012.12.012","article-title":"Selective inhibition of the West Nile virus methyltransferase by nucleoside analogs","volume":"97","author":"Chen","year":"2013","journal-title":"Antivir. Res."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"4016","DOI":"10.1021\/acs.jmedchem.5b00327","article-title":"5\u2032-Silylated 3\u2032-1,2,3-triazolyl Thymidine Analogues as Inhibitors of West Nile Virus and Dengue Virus","volume":"58","author":"Vernekar","year":"2015","journal-title":"J. Med. Chem."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"3365","DOI":"10.1021\/jo0255476","article-title":"\u201cFleximers\u201d. Design and synthesis of a new class of novel shape-modified nucleosides (1)","volume":"67","author":"Seley","year":"2002","journal-title":"J. Org. Chem."},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"Yates, M.K., Chatterjee, P., Flint, M., Arefeayne, Y., Makuc, D., Plavec, J., Spiropoulou, C.F., and Seley-Radtke, K.L. (2019). Probing the Effects of Pyrimidine Functional Group Switches on Acyclic Fleximer Analogues for Antiviral Activity. Molecules, 24.","DOI":"10.3390\/molecules24173184"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"115713","DOI":"10.1016\/j.bmc.2020.115713","article-title":"Synthesis and biological evaluation of novel flexible nucleoside analogues that inhibit flavivirus replication in vitro","volume":"28","author":"Thames","year":"2020","journal-title":"Bioorg. Med. Chem."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1128\/JVI.79.3.1943-1947.2005","article-title":"The predominant mechanism by which ribavirin exerts its antiviral activity in vitro against flaviviruses and paramyxoviruses is mediated by inhibition of IMP dehydrogenase","volume":"79","author":"Leyssen","year":"2005","journal-title":"J. Virol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"8292","DOI":"10.1128\/JVI.00599-15","article-title":"mRNA Capping by Venezuelan Equine Encephalitis Virus nsP1: Functional Characterization and Implications for Antiviral Research","volume":"89","author":"Li","year":"2015","journal-title":"J. Virol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.antiviral.2010.04.007","article-title":"A novel nucleoside analog, 1-beta-d-ribofuranosyl-3-ethynyl-[1,2,4]triazole (ETAR), exhibits efficacy against a broad range of flaviviruses in vitro","volume":"87","author":"McDowell","year":"2010","journal-title":"Antivir. Res."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0166-3542(02)00185-7","article-title":"Interferon, ribavirin, 6-azauridine and glycyrrhizin: Antiviral compounds active against pathogenic flaviviruses","volume":"58","author":"Crance","year":"2003","journal-title":"Antivir. Res."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S0166-3542(02)00013-X","article-title":"Identification of active antiviral compounds against a New York isolate of West Nile virus","volume":"55","author":"Morrey","year":"2002","journal-title":"Antivir. Res."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.antiviral.2016.11.018","article-title":"Evaluation of anti-Zika virus activities of broad-spectrum antivirals and NIH clinical collection compounds using a cell-based, high-throughput screen assay","volume":"138","author":"Adcock","year":"2017","journal-title":"Antivir. Res."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1081\/NCN-200060228","article-title":"Synthesis of 5-aza-7-deazaguanine nucleoside derivatives as potential anti-flavivirus agents","volume":"24","author":"Dukhan","year":"2005","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.plipres.2016.09.005","article-title":"Lipids and flaviviruses, present and future perspectives for the control of dengue, Zika, and West Nile viruses","volume":"64","author":"Saiz","year":"2016","journal-title":"Prog. Lipid Res."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.chom.2010.10.006","article-title":"Dengue virus-induced autophagy regulates lipid metabolism","volume":"8","author":"Heaton","year":"2010","journal-title":"Cell Host Microbe"},{"key":"ref_93","doi-asserted-by":"crossref","unstructured":"Perera, R., Riley, C., Isaac, G., Hopf-Jannasch, A.S., Moore, R.J., Weitz, K.W., Pasa-Tolic, L., Metz, T.O., Adamec, J., and Kuhn, R.J. (2012). Dengue virus infection perturbs lipid homeostasis in infected mosquito cells. PLoS Pathog., 8.","DOI":"10.1371\/journal.ppat.1002584"},{"key":"ref_94","doi-asserted-by":"crossref","unstructured":"Samsa, M.M., Mondotte, J.A., Iglesias, N.G., Assuncao-Miranda, I., Barbosa-Lima, G., Da Poian, A.T., Bozza, P.T., and Gamarnik, A.V. (2009). Dengue virus capsid protein usurps lipid droplets for viral particle formation. PLoS Pathog., 5.","DOI":"10.1371\/journal.ppat.1000632"},{"key":"ref_95","doi-asserted-by":"crossref","unstructured":"Martin-Acebes, M.A., Jimenez de Oya, N., and Saiz, J.C. (2019). Lipid Metabolism as a Source of Druggable Targets for Antiviral Discovery against Zika and Other Flaviviruses. Pharmaceuticals, 12.","DOI":"10.3390\/ph12020097"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"e00360-18","DOI":"10.1128\/AAC.00360-18","article-title":"Direct Activation of Adenosine Monophosphate-Activated Protein Kinase (AMPK) by PF-06409577 Inhibits Flavivirus Infection through Modification of Host Cell Lipid Metabolism","volume":"62","author":"Blazquez","year":"2018","journal-title":"Antimicrob. Agents. Chemother."},{"key":"ref_97","doi-asserted-by":"crossref","unstructured":"Soto-Acosta, R., Bautista-Carbajal, P., Cervantes-Salazar, M., Angel-Ambrocio, A.H., and Del Angel, R.M. (2017). DENV up-regulates the HMG-CoA reductase activity through the impairment of AMPK phosphorylation: A potential antiviral target. PLoS Pathog., 13.","DOI":"10.1371\/journal.ppat.1006257"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"8743","DOI":"10.1038\/s41598-021-87707-9","article-title":"The antiviral effect of metformin on zika and dengue virus infection","volume":"11","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"3344","DOI":"10.1038\/s41598-018-21612-6","article-title":"Metformin use and severe dengue in diabetic adults","volume":"8","author":"Htun","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1080\/22221751.2019.1604084","article-title":"Targeting host metabolism by inhibition of acetyl-Coenzyme A carboxylase reduces flavivirus infection in mouse models","volume":"8","author":"Esler","year":"2019","journal-title":"Emerg. Microbes Infect."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1038\/s41598-020-58468-8","article-title":"Evaluation of the antiviral activity of orlistat (tetrahydrolipstatin) against dengue virus, Japanese encephalitis virus, Zika virus and chikungunya virus","volume":"10","author":"Hitakarun","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"12041","DOI":"10.1128\/JVI.02061-14","article-title":"The composition of West Nile virus lipid envelope unveils a role of sphingolipid metabolism in flavivirus biogenesis","volume":"88","author":"Blazquez","year":"2014","journal-title":"J. Virol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/s41421-018-0017-2","article-title":"Zika virus propagation and release in human fetal astrocytes can be suppressed by neutral sphingomyelinase-2 inhibitor GW4869","volume":"4","author":"Huang","year":"2018","journal-title":"Cell Discov."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"749770","DOI":"10.3389\/fphys.2021.749770","article-title":"Anti-flavivirus Properties of Lipid-Lowering Drugs","volume":"12","year":"2021","journal-title":"Front. Physiol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.ijid.2015.04.019","article-title":"Treating Ebola patients: A \u2018bottom up\u2019 approach using generic statins and angiotensin receptor blockers","volume":"36","author":"Fedson","year":"2015","journal-title":"Int. J. Infect. Dis."},{"key":"ref_106","doi-asserted-by":"crossref","unstructured":"Martinez-Gutierrez, M., Correa-Londono, L.A., Castellanos, J.E., Gallego-Gomez, J.C., and Osorio, J.E. (2014). Lovastatin delays infection and increases survival rates in AG129 mice infected with dengue virus serotype 2. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0087412"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1186\/1745-6215-13-203","article-title":"Lovastatin for adult patients with dengue: Protocol for a randomised controlled trial","volume":"13","author":"Whitehorn","year":"2012","journal-title":"Trials"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.antiviral.2018.10.024","article-title":"Ezetimibe inhibits dengue virus infection in Huh-7 cells by blocking the cholesterol transporter Niemann-Pick C1-like 1 receptor","volume":"160","year":"2018","journal-title":"Antivir. Res."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1021\/cb800176t","article-title":"Antiviral compounds discovered by virtual screening of small-molecule libraries against dengue virus E protein","volume":"3","author":"Zhou","year":"2008","journal-title":"ACS Chem. Biol."},{"key":"ref_110","doi-asserted-by":"crossref","unstructured":"Gao, Y., Tai, W., Wang, N., Li, X., Jiang, S., Debnath, A.K., Du, L., and Chen, S. (2019). Identification of Novel Natural Products as Effective and Broad-Spectrum Anti-Zika Virus Inhibitors. Viruses, 11.","DOI":"10.3390\/v11111019"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"15672","DOI":"10.1038\/ncomms15672","article-title":"A peptide-based viral inactivator inhibits Zika virus infection in pregnant mice and fetuses","volume":"8","author":"Yu","year":"2017","journal-title":"Nat. Commun."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1128\/AAC.01429-12","article-title":"A novel inhibitor of dengue virus replication that targets the capsid protein","volume":"57","author":"Byrd","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1002\/jmv.22234","article-title":"Antiviral activity of arbidol, a broad-spectrum drug for use against respiratory viruses, varies according to test conditions","volume":"84","author":"Brooks","year":"2012","journal-title":"J. Med. Virol."},{"key":"ref_114","doi-asserted-by":"crossref","unstructured":"Haviernik, J., Stefanik, M., Fojtikova, M., Kali, S., Tordo, N., Rudolf, I., Hubalek, Z., Eyer, L., and Ruzek, D. (2018). Arbidol (Umifenovir): A Broad-Spectrum Antiviral Drug That Inhibits Medically Important Arthropod-Borne Flaviviruses. Viruses, 10.","DOI":"10.20944\/preprints201802.0134.v1"},{"key":"ref_115","doi-asserted-by":"crossref","unstructured":"Beck, S., Zhu, Z., Oliveira, M.F., Smith, D.M., Rich, J.N., Bernatchez, J.A., and Siqueira-Neto, J.L. (2019). Mechanism of Action of Methotrexate against Zika Virus. Viruses, 11.","DOI":"10.3390\/v11040338"},{"key":"ref_116","doi-asserted-by":"crossref","unstructured":"Scroggs, S.L.P., Andrade, C.C., Chinnasamy, R., Azar, S.R., Schirtzinger, E.E., Garcia, E.I., Arterburn, J.B., Hanley, K.A., and Rossi, S.L. (2020). Old Drugs with New Tricks: Efficacy of Fluoroquinolones to Suppress Replication of Flaviviruses. Viruses, 12.","DOI":"10.1101\/2020.03.30.016022"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"3032","DOI":"10.1016\/j.celrep.2017.11.054","article-title":"A Small-Molecule Oligosaccharyltransferase Inhibitor with Pan-flaviviral Activity","volume":"21","author":"Puschnik","year":"2017","journal-title":"Cell Rep."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1007\/s00705-021-05021-1","article-title":"Evaluation of kinase inhibitors as potential therapeutics for flavivirus infections","volume":"166","author":"Valencia","year":"2021","journal-title":"Arch. Virol."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"e00289-20","DOI":"10.1128\/AAC.00289-20","article-title":"Identification of Estrogen Receptor Modulators as Inhibitors of Flavivirus Infection","volume":"64","author":"Eyre","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"104749","DOI":"10.1016\/j.antiviral.2020.104749","article-title":"Antiviral activity of the natural alkaloid anisomycin against dengue and Zika viruses","volume":"176","author":"Quintana","year":"2020","journal-title":"Antivir. Res."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1128\/AAC.04177-14","article-title":"The bioactive lipid 4-hydroxyphenyl retinamide inhibits flavivirus replication","volume":"59","author":"Carocci","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.antiviral.2017.10.014","article-title":"Antiviral activity of N-(4-hydroxyphenyl) retinamide (4-HPR) against Zika virus","volume":"147","author":"Pitts","year":"2017","journal-title":"Antivir. Res."}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/14\/6\/1226\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:24:44Z","timestamp":1760138684000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/14\/6\/1226"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,5]]},"references-count":122,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2022,6]]}},"alternative-id":["v14061226"],"URL":"https:\/\/doi.org\/10.3390\/v14061226","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,5]]}}}